e10vq
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
Form 10-Q
(Mark One)
|
|
þ
|
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
|
SECURITIES EXCHANGE ACT OF
1934
For the quarterly period ended September 30, 2007
OR
|
|
o |
TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
|
SECURITIES EXCHANGE ACT OF
1934
For the transition period
from
to .
Commission file number 1-5353
TELEFLEX INCORPORATED
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
|
|
23-1147939
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(I.R.S. Employer Identification
No.)
|
|
|
|
155 South Limerick Road,
Limerick, Pennsylvania
|
|
19468
|
(Address of principal executive
offices)
|
|
(Zip Code)
|
(610) 948-5100
(Registrants telephone
number, including area code)
(None)
(Former Name, Former Address and
Former Fiscal Year, If Changed Since Last Report)
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, or a non-accelerated
filer (as defined in Exchange Act
Rule 12b-2).
Large accelerated
filer þ Accelerated
filer o Non-accelerated
filer o
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Act).
Yes o No þ
Indicate the number of shares outstanding of each of the
issuers classes of Common Stock, as of October 22,
2007:
|
|
|
Common Stock, $1.00 Par Value
|
|
39,497,040
|
(Title of each class)
|
|
(Number of shares)
|
TELEFLEX
INCORPORATED
QUARTERLY REPORT ON
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2007
TABLE OF
CONTENTS
1
PART I
FINANCIAL INFORMATION
|
|
Item 1.
|
Financial
Statements
|
TELEFLEX
INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 24,
|
|
|
September 30,
|
|
|
September 24,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars and shares in thousands, except per share)
|
|
|
Revenues
|
|
$
|
656,064
|
|
|
$
|
605,525
|
|
|
$
|
2,003,124
|
|
|
$
|
1,855,592
|
|
Materials, labor and other product costs
|
|
|
462,325
|
|
|
|
424,907
|
|
|
|
1,387,187
|
|
|
|
1,299,075
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
193,739
|
|
|
|
180,618
|
|
|
|
615,937
|
|
|
|
556,517
|
|
Selling, engineering and administrative expenses
|
|
|
126,774
|
|
|
|
112,930
|
|
|
|
394,604
|
|
|
|
361,071
|
|
Net (gain) loss on sales of assets
|
|
|
(207
|
)
|
|
|
(453
|
)
|
|
|
1,121
|
|
|
|
732
|
|
Restructuring and impairment charges
|
|
|
5,398
|
|
|
|
3,275
|
|
|
|
6,999
|
|
|
|
16,243
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before interest, taxes and
minority interest
|
|
|
61,774
|
|
|
|
64,866
|
|
|
|
213,213
|
|
|
|
178,471
|
|
Interest expense
|
|
|
10,117
|
|
|
|
10,283
|
|
|
|
29,147
|
|
|
|
31,158
|
|
Interest income
|
|
|
(4,871
|
)
|
|
|
(1,742
|
)
|
|
|
(8,301
|
)
|
|
|
(4,877
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before taxes and minority
interest
|
|
|
56,528
|
|
|
|
56,325
|
|
|
|
192,367
|
|
|
|
152,190
|
|
Taxes on income from continuing operations
|
|
|
105,687
|
|
|
|
15,002
|
|
|
|
140,708
|
|
|
|
37,755
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from continuing operations before minority interest
|
|
|
(49,159
|
)
|
|
|
41,323
|
|
|
|
51,659
|
|
|
|
114,435
|
|
Minority interest in consolidated subsidiaries, net of tax
|
|
|
7,680
|
|
|
|
6,627
|
|
|
|
22,416
|
|
|
|
18,215
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from continuing operations
|
|
|
(56,839
|
)
|
|
|
34,696
|
|
|
|
29,243
|
|
|
|
96,220
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income from discontinued operations (including
(loss) gain on disposal of $(275), $(401), $75,215 and $663,
respectively)
|
|
|
(275
|
)
|
|
|
1,972
|
|
|
|
80,485
|
|
|
|
8,001
|
|
Taxes on (loss) income from discontinued operations
|
|
|
(78
|
)
|
|
|
702
|
|
|
|
28,629
|
|
|
|
2,510
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from discontinued operations
|
|
|
(197
|
)
|
|
|
1,270
|
|
|
|
51,856
|
|
|
|
5,491
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income
|
|
$
|
(57,036
|
)
|
|
$
|
35,966
|
|
|
$
|
81,099
|
|
|
$
|
101,711
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from continuing operations
|
|
$
|
(1.44
|
)
|
|
$
|
0.88
|
|
|
$
|
0.75
|
|
|
$
|
2.40
|
|
(Loss) income from discontinued operations
|
|
$
|
(0.01
|
)
|
|
$
|
0.03
|
|
|
$
|
1.32
|
|
|
$
|
0.14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income
|
|
$
|
(1.45
|
)
|
|
$
|
0.91
|
|
|
$
|
2.07
|
|
|
$
|
2.54
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from continuing operations
|
|
$
|
(1.44
|
)
|
|
$
|
0.88
|
|
|
$
|
0.74
|
|
|
$
|
2.39
|
|
(Loss) income from discontinued operations
|
|
$
|
(0.01
|
)
|
|
$
|
0.03
|
|
|
$
|
1.31
|
|
|
$
|
0.14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income
|
|
$
|
(1.45
|
)
|
|
$
|
0.91
|
|
|
$
|
2.05
|
|
|
$
|
2.53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends per share
|
|
$
|
0.32
|
|
|
$
|
0.285
|
|
|
$
|
0.925
|
|
|
$
|
0.820
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
39,368
|
|
|
|
39,465
|
|
|
|
39,207
|
|
|
|
40,019
|
|
Diluted
|
|
|
39,368
|
|
|
|
39,566
|
|
|
|
39,638
|
|
|
|
40,241
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
2
TELEFLEX
INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in thousands)
|
|
|
ASSETS
|
Current assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
497,724
|
|
|
$
|
248,409
|
|
Accounts receivable, net
|
|
|
396,481
|
|
|
|
376,404
|
|
Inventories
|
|
|
420,807
|
|
|
|
415,879
|
|
Prepaid expenses
|
|
|
23,210
|
|
|
|
27,689
|
|
Deferred tax assets
|
|
|
66,842
|
|
|
|
60,963
|
|
Assets held for sale
|
|
|
2,760
|
|
|
|
10,185
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
1,407,824
|
|
|
|
1,139,529
|
|
Property, plant and equipment, net
|
|
|
388,577
|
|
|
|
422,178
|
|
Goodwill
|
|
|
534,208
|
|
|
|
514,006
|
|
Intangibles and other assets
|
|
|
285,514
|
|
|
|
259,229
|
|
Investments in affiliates
|
|
|
28,072
|
|
|
|
23,076
|
|
Deferred tax assets
|
|
|
4,608
|
|
|
|
3,419
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
2,648,803
|
|
|
$
|
2,361,437
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
Current liabilities
|
|
|
|
|
|
|
|
|
Current borrowings
|
|
$
|
80,562
|
|
|
$
|
31,022
|
|
Accounts payable
|
|
|
214,707
|
|
|
|
210,890
|
|
Accrued expenses
|
|
|
112,154
|
|
|
|
115,657
|
|
Payroll and benefit-related liabilities
|
|
|
85,766
|
|
|
|
74,407
|
|
Income taxes payable
|
|
|
50,203
|
|
|
|
16,125
|
|
Deferred tax liabilities
|
|
|
1,099
|
|
|
|
164
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
544,491
|
|
|
|
448,265
|
|
Long-term borrowings
|
|
|
455,878
|
|
|
|
487,370
|
|
Deferred tax liabilities
|
|
|
130,005
|
|
|
|
25,272
|
|
Pension and postretirement benefit liabilities
|
|
|
87,111
|
|
|
|
97,191
|
|
Other liabilities
|
|
|
96,317
|
|
|
|
71,861
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
1,313,802
|
|
|
|
1,129,959
|
|
Minority interest in equity of consolidated subsidiaries
|
|
|
44,941
|
|
|
|
42,057
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Shareholders equity
|
|
|
1,290,060
|
|
|
|
1,189,421
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders equity
|
|
$
|
2,648,803
|
|
|
$
|
2,361,437
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
3
TELEFLEX
INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 24,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in thousands)
|
|
|
Cash Flows from Operating Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
81,099
|
|
|
$
|
101,711
|
|
Adjustments to reconcile net income to net cash provided by
operating activities:
|
|
|
|
|
|
|
|
|
Income from discontinued operations
|
|
|
(51,856
|
)
|
|
|
(5,491
|
)
|
Depreciation expense
|
|
|
55,497
|
|
|
|
56,814
|
|
Amortization expense of intangible assets
|
|
|
11,096
|
|
|
|
10,037
|
|
Amortization expense of deferred financing costs
|
|
|
838
|
|
|
|
963
|
|
Stock-based compensation
|
|
|
6,404
|
|
|
|
5,100
|
|
Net loss on sales of assets
|
|
|
1,121
|
|
|
|
732
|
|
Impairment of long-lived assets
|
|
|
4,118
|
|
|
|
5,230
|
|
Minority interest in consolidated subsidiaries
|
|
|
22,416
|
|
|
|
18,215
|
|
Other
|
|
|
(2,291
|
)
|
|
|
592
|
|
Changes in operating assets and liabilities, net of effects of
acquisitions:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(25,150
|
)
|
|
|
29,054
|
|
Inventories
|
|
|
(3,187
|
)
|
|
|
(7,962
|
)
|
Prepaid expenses
|
|
|
(8,111
|
)
|
|
|
(4,718
|
)
|
Accounts payable and accrued expenses
|
|
|
10,399
|
|
|
|
(4,741
|
)
|
Income taxes payable and deferred income taxes
|
|
|
105,649
|
|
|
|
(5,159
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities from continuing
operations
|
|
|
208,042
|
|
|
|
200,377
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Proceeds from long-term borrowings
|
|
|
49,203
|
|
|
|
|
|
Reduction in long-term borrowings
|
|
|
(30,689
|
)
|
|
|
(33,402
|
)
|
Decrease in notes payable and current borrowings
|
|
|
(7,272
|
)
|
|
|
(60,789
|
)
|
Proceeds from stock compensation plans
|
|
|
23,167
|
|
|
|
8,939
|
|
Payments to minority interest shareholders
|
|
|
(21,259
|
)
|
|
|
(618
|
)
|
Purchases of treasury stock
|
|
|
|
|
|
|
(93,552
|
)
|
Dividends
|
|
|
(36,321
|
)
|
|
|
(33,006
|
)
|
|
|
|
|
|
|
|
|
|
Net cash used in financing activities from continuing operations
|
|
|
(23,171
|
)
|
|
|
(212,428
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Expenditures for property, plant and equipment
|
|
|
(37,109
|
)
|
|
|
(39,568
|
)
|
Payments for businesses acquired
|
|
|
(43,689
|
)
|
|
|
(4,334
|
)
|
Proceeds from sales of businesses and assets
|
|
|
142,303
|
|
|
|
3,643
|
|
(Investments in) proceeds from affiliates
|
|
|
(5,439
|
)
|
|
|
3,002
|
|
Working capital payment for divested business
|
|
|
|
|
|
|
(6,029
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities from
continuing operations
|
|
|
56,066
|
|
|
|
(43,286
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Discontinued Operations:
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
5,607
|
|
|
|
14,175
|
|
Net cash used in investing activities
|
|
|
(4,632
|
)
|
|
|
(2,868
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by discontinued operations
|
|
|
975
|
|
|
|
11,307
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
7,403
|
|
|
|
6,919
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
249,315
|
|
|
|
(37,111
|
)
|
Cash and cash equivalents at the beginning of the period
|
|
|
248,409
|
|
|
|
239,536
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at the end of the period
|
|
$
|
497,724
|
|
|
$
|
202,425
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
4
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
|
|
Note 1
|
Basis of
presentation
|
Teleflex Incorporated (the Company) is a diversified
company specializing in the design, manufacture and distribution
of specialty-engineered products. The Company serves a wide
range of customers in niche segments of the commercial, medical
and aerospace industries. The Companys products include:
driver controls, motion controls, power and vehicle management
systems and fluid management systems for commercial industries;
disposable medical products, surgical instruments, medical
devices and specialty devices for hospitals and health-care
providers; and repair products and services and cargo-handling
systems for commercial aviation.
The accompanying condensed consolidated financial statements of
the Company have been prepared in accordance with accounting
principles generally accepted in the United States of America
for interim financial information and in accordance with the
instructions for
Form 10-Q
and
Rule 10-01
of
Regulation S-X.
Accordingly, they do not include all information and footnotes
required by accounting principles generally accepted in the
United States of America for complete financial statements.
The accompanying financial information is unaudited; however, in
the opinion of the Companys management, all adjustments
(consisting of normal recurring adjustments and accruals)
necessary for a fair statement of the financial position,
results of operations and cash flows for the periods reported
have been included. The results of operations for the periods
reported are not necessarily indicative of those that may be
expected for a full year.
This quarterly report should be read in conjunction with the
consolidated financial statements and notes thereto included in
the Companys audited consolidated financial statements for
the fiscal year ended December 31, 2006 presented in the
Companys Current Report on
Form 8-K
filed with the Securities and Exchange Commission on
October 3, 2007.
During the third quarter of 2007, the Company recorded
adjustments to correct its financial statements. These
adjustments increased the loss from continuing operations by
$2.9 million. Based on the Companys analysis of these
matters, the Company has concluded that these matters were not
material on a quantitative or qualitative basis to the current
period or any previously filed financial information.
Certain reclassifications have been made to the prior year
condensed consolidated financial statements to conform to
current period presentation. Certain financial information is
presented on a rounded basis, which may cause minor differences.
|
|
Note 2
|
New
accounting standards
|
Uncertain Tax Positions: In June 2006, the
Financial Accounting Standards Board (FASB) issued
Interpretation (FIN) No. 48, Accounting
for Uncertainty in Income Taxes an interpretation of
FASB Statement No. 109. FIN No. 48
clarifies the accounting for uncertainty in income taxes
recognized in an enterprises financial statements in
accordance with SFAS No. 109, Accounting for
Income Taxes. FIN No. 48 requires that the
impact of a tax position be recognized in the financial
statements if it is more likely than not that the tax position
will be sustained on tax audit, based on the technical merits of
the position. FIN No. 48 also provides guidance on
derecognition of tax positions that do not meet the more
likely than not standard, classification of tax assets and
liabilities, interest and penalties, accounting in interim
periods, disclosure and transition. The provisions of
FIN No. 48 are effective for fiscal years beginning
after December 15, 2006. In connection with its adoption of
the provisions of FIN No. 48 on January 1, 2007,
the Company recognized a charge of approximately
$13.2 million to retained earnings.
See Note 11 for additional information regarding the
Companys uncertain tax positions.
Fair Value Measurements: In September 2006,
the FASB issued Statement of Financial Accounting Standards
(SFAS) No. 157, Fair Value
Measurements, which defines fair value, establishes
guidelines for measuring fair value and expands disclosures
regarding fair value measurements. SFAS No. 157 does
not require any new fair value measurements but rather
eliminates inconsistencies in guidance found in various prior
accounting pronouncements. The provisions of
SFAS No. 157 are effective for fiscal years beginning
after November 15, 2007. The Company is currently
evaluating the impact of SFAS No. 157 on the
Companys financial position, results of operations and
cash flows.
5
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Fair Value Option: In February 2007, the FASB
issued SFAS No. 159, The Fair Value Option for
Financial Assets and Financial Liabilities including
an amendment of FASB Statement No. 115, which permits
an entity to measure certain financial assets and financial
liabilities at fair value, with unrealized gains and losses
reported in earnings at each subsequent measurement date. The
fair value option may be elected on an
instrument-by-instrument
basis, as long as it is applied to the instrument in its
entirety. The fair value option election is irrevocable, unless
an event specified in SFAS No. 159 occurs that results
in a new election date. This statement is effective for fiscal
years beginning after November 15, 2007. The Company is
currently evaluating the impact of SFAS No. 159 on the
Companys financial position, results of operations and
cash flows.
Acquisition
of Specialized Medical Devices, Inc.
In April 2007, the Company acquired the assets of HDJ Company,
Inc. (HDJ) and its wholly owned subsidiary,
Specialized Medical Devices, Inc. (SMD), a provider
of engineering and manufacturing services to medical device
manufacturers, for approximately $25.0 million. The results
for HDJ are included in the Companys Medical Segment.
Acquisition
of Southern Wire Corporation.
In April 2007, the Company acquired substantially all of the
assets of Southern Wire Corporation (Southern Wire),
a wholesale distributor of wire rope cables and related
hardware, for approximately $20.4 million. The results for
Southern Wire are included in the Companys Commercial
Segment.
Acquisition
of Taut, Inc.
On November 8, 2006, the Company completed the acquisition
of substantially all of the assets of Taut Inc.
(Taut), a provider of instruments and devices for
minimally invasive surgical procedures, particularly
laparoscopic surgery, for approximately $28.0 million. The
results for Taut are included in the Companys Medical
Segment.
During the first quarter of 2007, the Company finalized the
purchase price allocation for the Taut acquisition. Based on the
revised allocation, an additional $1.4 million and
$4.0 million was allocated to inventories and intangible
assets, respectively. These amounts were previously allocated to
goodwill.
Acquisition
of Ecotrans Technologies, Inc.
On November 30, 2006, the Company completed the acquisition
of all of the issued and outstanding capital stock of Ecotrans
Technologies, Inc. (Ecotrans), a supplier of
locomotive anti-idling and emissions reduction solutions for the
railroad industry, for approximately $10.1 million. During
the first nine months of 2007, the Company finalized the
purchase price allocation and recognized an additional
$1.0 million of goodwill. The results for Ecotrans are
included in the Companys Commercial Segment.
6
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The amounts recognized in restructuring and impairment charges
for the three months and nine months ended September 30,
2007 and September 24, 2006 consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 24,
|
|
|
September 30,
|
|
|
September 24,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in thousands)
|
|
|
2006 restructuring program
|
|
$
|
1,568
|
|
|
$
|
825
|
|
|
$
|
2,567
|
|
|
$
|
2,648
|
|
Aerospace Segment restructuring activity
|
|
|
|
|
|
|
307
|
|
|
|
(3
|
)
|
|
|
613
|
|
2004 restructuring and divestiture program
|
|
|
73
|
|
|
|
2,143
|
|
|
|
678
|
|
|
|
9,114
|
|
Impairment charges
|
|
|
3,757
|
|
|
|
|
|
|
|
3,757
|
|
|
|
3,868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
5,398
|
|
|
$
|
3,275
|
|
|
$
|
6,999
|
|
|
$
|
16,243
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006
Restructuring Program
In June 2006, the Company began certain restructuring
initiatives that affect all three of the Companys
operating segments. These initiatives involve the consolidation
of operations and a related reduction in workforce at several of
the Companys facilities in Europe and North America. The
Company determined to undertake these initiatives as a means to
improving operating performance and to better leverage the
Companys existing resources.
For the three months and nine months ended September 30,
2007, the charges, including changes in estimates, associated
with the 2006 restructuring program by segment that are included
in restructuring and impairment charges were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, 2007
|
|
|
|
Commercial
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
203
|
|
|
$
|
61
|
|
|
$
|
50
|
|
|
$
|
314
|
|
Contract termination costs
|
|
|
|
|
|
|
320
|
|
|
|
48
|
|
|
|
368
|
|
Asset impairments
|
|
|
|
|
|
|
|
|
|
|
361
|
|
|
|
361
|
|
Other restructuring costs
|
|
|
515
|
|
|
|
10
|
|
|
|
|
|
|
|
525
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
718
|
|
|
$
|
391
|
|
|
$
|
459
|
|
|
$
|
1,568
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2007
|
|
|
|
Commercial
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
203
|
|
|
$
|
775
|
|
|
$
|
129
|
|
|
$
|
1,107
|
|
Contract termination costs
|
|
|
|
|
|
|
411
|
|
|
|
48
|
|
|
|
459
|
|
Asset impairments
|
|
|
|
|
|
|
|
|
|
|
361
|
|
|
|
361
|
|
Other restructuring costs
|
|
|
595
|
|
|
|
45
|
|
|
|
|
|
|
|
640
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
798
|
|
|
$
|
1,231
|
|
|
$
|
538
|
|
|
$
|
2,567
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
For the three and the nine months ended September 24, 2006,
the charges associated with the 2006 restructuring program by
segment that are included in restructuring and impairment
charges were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 24, 2006
|
|
|
|
Commercial
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
|
|
|
$
|
155
|
|
|
$
|
650
|
|
|
$
|
805
|
|
Other restructuring costs
|
|
|
|
|
|
|
20
|
|
|
|
|
|
|
|
20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
175
|
|
|
$
|
650
|
|
|
$
|
825
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 24, 2006
|
|
|
|
Commercial
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
485
|
|
|
$
|
1,419
|
|
|
$
|
650
|
|
|
$
|
2,554
|
|
Other restructuring costs
|
|
|
|
|
|
|
94
|
|
|
|
|
|
|
|
94
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
485
|
|
|
$
|
1,513
|
|
|
$
|
650
|
|
|
$
|
2,648
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination benefits are comprised of severance-related payments
for all employees terminated in connection with the 2006
restructuring program. Contract termination costs relate
primarily to the termination of leases in conjunction with the
consolidation of facilities. Asset impairments relate to
leasehold improvements associated with the closure of a
facility. Other restructuring costs include expenses primarily
related to the consolidation of operations and the
reorganization of administrative functions.
At September 30, 2007, the accrued liability associated
with the 2006 restructuring program consisted of the following
and, except for contract termination costs, management expects
these will be paid within one year:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
Accruals and
|
|
|
|
|
|
Balance at
|
|
|
|
December 31,
|
|
|
Changes in
|
|
|
|
|
|
September 30,
|
|
|
|
2006
|
|
|
Estimates
|
|
|
Payments
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
3,406
|
|
|
$
|
1,107
|
|
|
$
|
(3,016
|
)
|
|
$
|
1,497
|
|
Contract termination costs
|
|
|
95
|
|
|
|
459
|
|
|
|
(158
|
)
|
|
|
396
|
|
Asset impairments
|
|
|
|
|
|
|
361
|
|
|
|
(361
|
)
|
|
|
|
|
Other restructuring costs
|
|
|
4
|
|
|
|
640
|
|
|
|
(644
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3,505
|
|
|
$
|
2,567
|
|
|
$
|
(4,179
|
)
|
|
$
|
1,893
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2007, the Company expects to incur the
following future restructuring costs associated with the 2006
restructuring program in its Commercial, Medical and Aerospace
segments through the second quarter of 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
|
|
|
Medical
|
|
|
Aerospace
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
1,300 - 1,600
|
|
|
$
|
1,100 - 1,500
|
|
|
$
|
200 - 300
|
|
Contract termination costs
|
|
|
|
|
|
|
|
|
|
|
50 - 100
|
|
Other restructuring costs
|
|
|
|
|
|
|
50 - 100
|
|
|
|
250 - 400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,300 - 1,600
|
|
|
$
|
1,150 - 1,600
|
|
|
$
|
500 - 800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Aerospace
Segment Restructuring Activity
During the first quarter of 2006, the Company began a
restructuring activity in its Aerospace Segment. The actions
related to the closure of a manufacturing facility, termination
of employees and relocation of operations. Actions under this
program are complete and there are no accrued liabilities at
September 30, 2007.
2004
Restructuring and Divestiture Program
During the fourth quarter of 2004, the Company announced and
commenced implementation of a restructuring and divestiture
program designed to improve future operating performance and
position the Company for future earnings growth. The actions
included exiting or divesting non-core or low performing
businesses, consolidating manufacturing operations and
reorganizing administrative functions to enable businesses to
share services.
For the three and nine months ended September 30, 2007 and
September 24, 2006, the charges, including changes in
estimates, associated with the 2004 restructuring and
divestiture program were incurred by the Companys Medical
Segment and are included in restructuring and impairment charges
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
Nine Months
|
|
|
|
Ended
|
|
|
Ended
|
|
|
|
September 30,
|
|
|
September 24,
|
|
|
September 30,
|
|
|
September 24,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
(34
|
)
|
|
$
|
68
|
|
|
$
|
(34
|
)
|
|
$
|
(20
|
)
|
Contract termination costs
|
|
|
|
|
|
|
221
|
|
|
|
|
|
|
|
954
|
|
Asset impairments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
927
|
|
Other restructuring costs
|
|
|
107
|
|
|
|
1,854
|
|
|
|
712
|
|
|
|
7,253
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
73
|
|
|
$
|
2,143
|
|
|
$
|
678
|
|
|
$
|
9,114
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination benefits are comprised of severance-related payments
for all employees terminated in connection with the 2004
restructuring and divestiture program. Contract termination
costs relate primarily to the termination of leases in
conjunction with the consolidation of facilities. Asset
impairments relate primarily to machinery and equipment
associated with the consolidation of manufacturing facilities.
Other restructuring costs include expenses primarily related to
the consolidation of manufacturing operations and the
reorganization of administrative functions.
At September 30, 2007, the accrued liability associated
with the 2004 restructuring and divestiture program consisted of
the following and, except for contract termination costs,
management expects these will be paid within one year:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
Accruals and
|
|
|
|
|
|
Balance at
|
|
|
|
December 31,
|
|
|
Changes in
|
|
|
|
|
|
September 30,
|
|
|
|
2006
|
|
|
Estimates
|
|
|
Payments
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
204
|
|
|
$
|
(34
|
)
|
|
$
|
(106
|
)
|
|
$
|
64
|
|
Contract termination costs
|
|
|
1,952
|
|
|
|
|
|
|
|
(619
|
)
|
|
|
1,333
|
|
Other restructuring costs
|
|
|
99
|
|
|
|
712
|
|
|
|
(811
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
2,255
|
|
|
$
|
678
|
|
|
$
|
(1,536
|
)
|
|
$
|
1,397
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2007, the Company does not expect to
incur additional restructuring expenses associated with the 2004
restructuring and divestiture program.
9
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Impairment
Charges
During October of 2007, the Company signed a letter of intent to
sell its ownership interest in one of its variable interest
entities. Based on the agreed selling price, the Company
determined that the carrying value of the entitys
long-lived assets was impaired and recorded a charge of
approximately $3.8 million which is included in
restructuring and impairment charges in 2007. During the second
quarter of 2006, the Company determined that an investment in a
nonconsolidated affiliate was impaired and recorded a charge of
approximately $3.9 million, which is included in
restructuring and impairment charges in 2006.
Inventories consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in thousands)
|
|
|
Raw materials
|
|
$
|
217,889
|
|
|
$
|
214,440
|
|
Work-in-process
|
|
|
50,335
|
|
|
|
65,058
|
|
Finished goods
|
|
|
201,903
|
|
|
|
182,954
|
|
|
|
|
|
|
|
|
|
|
|
|
|
470,127
|
|
|
|
462,452
|
|
Less: Inventory reserve
|
|
|
(49,320
|
)
|
|
|
(46,573
|
)
|
|
|
|
|
|
|
|
|
|
Inventories
|
|
$
|
420,807
|
|
|
$
|
415,879
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 6
|
Goodwill
and other intangible assets
|
Changes in the carrying amount of goodwill, by operating
segment, for the nine months ended September 30, 2007 are
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Goodwill at December 31, 2006
|
|
$
|
114,878
|
|
|
$
|
391,830
|
|
|
$
|
7,298
|
|
|
$
|
514,006
|
|
Acquisitions
|
|
|
5,565
|
|
|
|
7,834
|
|
|
|
|
|
|
|
13,399
|
|
Dispositions
|
|
|
|
|
|
|
|
|
|
|
(981
|
)
|
|
|
(981
|
)
|
Impairment charges
|
|
|
(2,448
|
)
|
|
|
|
|
|
|
|
|
|
|
(2,448
|
)
|
Adjustments(1)
|
|
|
963
|
|
|
|
(2,189
|
)
|
|
|
|
|
|
|
(1,226
|
)
|
Translation adjustment
|
|
|
9,101
|
|
|
|
2,357
|
|
|
|
|
|
|
|
11,458
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill at September 30, 2007
|
|
$
|
128,059
|
|
|
$
|
399,832
|
|
|
$
|
6,317
|
|
|
$
|
534,208
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Goodwill adjustments relate primarily to purchase price
allocation changes associated with the Taut and Ecotrans
acquisitions (see Note 3) and the purchase of shares
from minority shareholders of a subsidiary in the Companys
Medical Segment. |
10
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Intangible assets consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Carrying Amount
|
|
|
Accumulated Amortization
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
|
|
|
|
(Dollars in thousands)
|
|
|
|
|
|
Customer lists
|
|
$
|
89,183
|
|
|
$
|
84,593
|
|
|
$
|
25,613
|
|
|
$
|
20,246
|
|
Intellectual property
|
|
|
81,180
|
|
|
|
68,476
|
|
|
|
33,554
|
|
|
|
28,388
|
|
Distribution rights
|
|
|
37,345
|
|
|
|
36,266
|
|
|
|
21,052
|
|
|
|
19,124
|
|
Trade names
|
|
|
96,771
|
|
|
|
90,252
|
|
|
|
222
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
304,479
|
|
|
$
|
279,587
|
|
|
$
|
80,441
|
|
|
$
|
67,758
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense related to intangible assets was
approximately $3.9 million and $10.8 million for the
three and nine months ended September 30, 2007,
respectively, and approximately $3.4 million and
$10.0 million for the three and nine months ended
September 24, 2006, respectively. Estimated annual
amortization expense for each of the five succeeding years is as
follows (dollars in thousands):
|
|
|
|
|
2007
|
|
$
|
14,700
|
|
2008
|
|
|
15,000
|
|
2009
|
|
|
14,800
|
|
2010
|
|
|
14,200
|
|
2011
|
|
|
13,600
|
|
|
|
Note 7
|
Comprehensive
income
|
The following table summarizes the components of comprehensive
income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 24,
|
|
|
September 30,
|
|
|
September 24,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in thousands)
|
|
|
Net (loss) income
|
|
$
|
(57,036
|
)
|
|
$
|
35,966
|
|
|
$
|
81,099
|
|
|
$
|
101,711
|
|
Net unrealized (loss) gains on qualifying cash flow hedges
|
|
|
(865
|
)
|
|
|
(300
|
)
|
|
|
1,542
|
|
|
|
1,680
|
|
Pension obligation amortization
|
|
|
514
|
|
|
|
|
|
|
|
1,734
|
|
|
|
|
|
Pension curtailment
|
|
|
|
|
|
|
|
|
|
|
1,484
|
|
|
|
|
|
Cumulative translation adjustment
|
|
|
23,171
|
|
|
|
2,632
|
|
|
|
37,758
|
|
|
|
30,862
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive (loss) income
|
|
$
|
(34,216
|
)
|
|
$
|
38,298
|
|
|
$
|
123,617
|
|
|
$
|
134,253
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 8
|
Changes
in shareholders equity
|
Set forth below is a reconciliation of the Companys issued
common shares:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 24,
|
|
|
September 30,
|
|
|
September 24,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
|
(Shares in thousands)
|
|
|
Common shares, beginning of period
|
|
|
41,694
|
|
|
|
41,282
|
|
|
|
41,364
|
|
|
|
41,123
|
|
Shares issued under compensation plans
|
|
|
92
|
|
|
|
21
|
|
|
|
422
|
|
|
|
180
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common shares, end of period
|
|
|
41,786
|
|
|
|
41,303
|
|
|
|
41,786
|
|
|
|
41,303
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
On June 14, 2007, the Companys Board of Directors
authorized the repurchase of up to $300 million of
outstanding Company common stock. Repurchases of Company stock
under the program may be made from time to time in the open
market and may include privately-negotiated transactions as
market conditions warrant and subject to regulatory
considerations. The stock repurchase program has no expiration
date and the Companys ability to execute on the program
will depend on, among other factors, cash requirements for
acquisitions, cash generation from operations, debt repayment
obligations, market conditions and regulatory requirements. In
addition under the senior loan agreements entered into
October 1, 2007, the Company is subject to certain
restrictions relating to its ability to repurchase shares in the
event the Companys consolidated leverage ratio exceeds
certain levels, which may further limit the Companys
ability to repurchase shares under this program. Through
September 30, 2007, no shares have been purchased under
this plan.
Basic earnings per share is computed by dividing net income by
the weighted average number of common shares outstanding during
the period. Diluted earnings per share is computed in the same
manner except that the weighted average number of shares is
increased for dilutive securities. The difference between basic
and diluted weighted average common shares results from the
assumption that dilutive stock options were exercised. A
reconciliation of basic to diluted weighted average shares
outstanding is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
Nine Months
|
|
|
|
Ended
|
|
|
Ended
|
|
|
|
September 30,
|
|
|
September 24,
|
|
|
September 30,
|
|
|
September 24,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
|
(Shares in thousands)
|
|
|
Basic
|
|
|
39,368
|
|
|
|
39,465
|
|
|
|
39,207
|
|
|
|
40,019
|
|
Dilutive shares assumed issued
|
|
|
|
|
|
|
101
|
|
|
|
431
|
|
|
|
222
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
39,368
|
|
|
|
39,566
|
|
|
|
39,638
|
|
|
|
40,241
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average stock options that were antidilutive and
therefore not included in the calculation of earnings per share
were approximately 666 thousand and 442 thousand for the three
and nine months ended September 30, 2007, respectively, and
693 thousand and 389 thousand for the three and nine months
ended September 24, 2006, respectively.
|
|
Note 9
|
Stock
compensation plans
|
The Company has a stock-based compensation plan that provides
for the granting of incentive and non-qualified options and
restricted stock units to directors, officers and key employees.
Under the plan, the Company is authorized to issue up to
4 million shares of common stock, but no more than 800,000
of those shares may be issued as restricted stock. Options
granted under the plan have an exercise price equal to the
average of the high and low sales prices of the Companys
common stock on the date of the grant, rounded to the nearest
$0.25. Generally, options granted under the plan are exercisable
three to five years after the date of the grant and expire no
more than ten years after the grant. Outstanding restricted
stock units generally vest in two to three years.
During the first nine months of 2007, the Company granted
incentive and non-qualified options to purchase
329,694 shares of common stock and granted restricted stock
units representing 92,839 shares of common stock.
|
|
Note 10
|
Pension
and other postretirement benefits
|
The Company has a number of defined benefit pension and
postretirement plans covering eligible U.S. and
non-U.S. employees.
The defined benefit pension plans are noncontributory. The
benefits under these plans are based primarily on years of
service and employees pay near retirement. The
Companys funding policy for U.S. plans is to
contribute annually, at a minimum, amounts required by
applicable laws and regulations. Obligations under
non-U.S. plans
are systematically provided for by depositing funds with
trustees or by book reserves.
12
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company and certain of its subsidiaries provide medical,
dental and life insurance benefits to pensioners and survivors.
The associated plans are unfunded and approved claims are paid
from Company funds.
Net benefit cost of pension and postretirement benefit plans
consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension
|
|
|
Other Benefits
|
|
|
Pension
|
|
|
Other Benefits
|
|
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 24,
|
|
|
September 30,
|
|
|
September 24,
|
|
|
September 30,
|
|
|
September 24,
|
|
|
September 30,
|
|
|
September 24,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in thousands)
|
|
|
Service cost
|
|
$
|
464
|
|
|
$
|
1,024
|
|
|
$
|
106
|
|
|
$
|
77
|
|
|
$
|
2,456
|
|
|
$
|
3,065
|
|
|
$
|
318
|
|
|
$
|
220
|
|
Interest cost
|
|
|
1,394
|
|
|
|
3,358
|
|
|
|
415
|
|
|
|
398
|
|
|
|
7,748
|
|
|
|
10,074
|
|
|
|
1,246
|
|
|
|
1,140
|
|
Expected return on plan assets
|
|
|
(1,222
|
)
|
|
|
(3,690
|
)
|
|
|
|
|
|
|
|
|
|
|
(8,044
|
)
|
|
|
(11,139
|
)
|
|
|
|
|
|
|
|
|
Net amortization and deferral
|
|
|
272
|
|
|
|
486
|
|
|
|
282
|
|
|
|
266
|
|
|
|
1,636
|
|
|
|
1,492
|
|
|
|
845
|
|
|
|
761
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net benefit cost
|
|
$
|
908
|
|
|
$
|
1,178
|
|
|
$
|
803
|
|
|
$
|
741
|
|
|
$
|
3,796
|
|
|
$
|
3,492
|
|
|
$
|
2,409
|
|
|
$
|
2,121
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 11
|
Commitments
and contingent liabilities
|
Product warranty liability: The Company
warrants to the original purchaser of certain of its products
that it will, at its option, repair or replace, without charge,
such products if they fail due to a manufacturing defect.
Warranty periods vary by product. The Company has recourse
provisions for certain products that would enable recovery from
third parties for amounts paid under the warranty. The Company
accrues for product warranties when, based on available
information, it is probable that customers will make claims
under warranties relating to products that have been sold, and a
reasonable estimate of the costs (based on historical claims
experience relative to sales) can be made. Set forth below is a
reconciliation of the Companys estimated product warranty
liability for the nine months ended September 30, 2007
(dollars in thousands):
|
|
|
|
|
Balance December 31, 2006
|
|
$
|
14,058
|
|
Accruals for warranties issued in 2007
|
|
|
8,200
|
|
Settlements (cash and in kind)
|
|
|
(9,923
|
)
|
Accruals related to pre-existing warranties
|
|
|
4,843
|
|
Effect of translation
|
|
|
1,409
|
|
|
|
|
|
|
Balance September 30, 2007
|
|
$
|
18,587
|
|
|
|
|
|
|
Operating leases: The Company uses various
leased facilities and equipment in its operations. The terms for
these leased assets vary depending on the lease agreement. In
connection with these operating leases, the Company had residual
value guarantees in the amount of approximately
$3.6 million at September 30, 2007. The Companys
future payments cannot exceed the minimum rent obligation plus
the residual value guarantee amount. The guarantee amounts are
tied to the unamortized lease values of the assets under lease,
and are due should the Company decide neither to renew these
leases, nor to exercise its purchase option. At
September 30, 2007, the Company had no liabilities recorded
for these obligations. Any residual value guarantee amounts paid
to the lessor may be recovered by the Company from the sale of
the assets to a third party.
Accounts receivable securitization
program: The Company uses an accounts receivable
securitization program to gain access to enhanced credit markets
and reduce financing costs. As currently structured, the Company
sells certain trade receivables on a non-recourse basis to a
consolidated special purpose entity, which in turn sells an
interest in those receivables to a commercial paper conduit. The
conduit issues notes secured by that interest to third party
investors. The assets of the special purpose entity are not
available to satisfy the obligations of the Company. In
accordance with the provisions of SFAS No. 140,
Accounting for Transfers and Servicing of Financial Assets
and Extinguishments of Liabilities, transfers of assets
under the program qualify as sales of
13
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
receivables and accordingly, approximately $39.7 million
and $40.1 million of accounts receivable and the related
amounts previously recorded in notes payable were removed from
the condensed consolidated balance sheet at September 30,
2007 and December 31, 2006, respectively.
Environmental: The Company is subject to
contingencies as a result of environmental laws and regulations
that in the future may require the Company to take further
action to correct the effects on the environment of prior
disposal practices or releases of chemical or petroleum
substances by the Company or other parties. Much of this
liability results from the U.S. Comprehensive Environmental
Response, Compensation and Liability Act (CERCLA),
often referred to as Superfund, the U.S. Resource
Conservation and Recovery Act (RCRA) and similar
state laws. These laws require the Company to undertake certain
investigative and remedial activities at sites where the Company
conducts or once conducted operations or at sites where
Company-generated waste was disposed.
Remediation activities vary substantially in duration and cost
from site to site. These activities, and their associated costs,
depend on the mix of unique site characteristics, evolving
remediation technologies, diverse regulatory agencies and
enforcement policies, as well as the presence or absence of
other potentially responsible parties. At September 30,
2007, the Companys condensed consolidated balance sheet
included an accrued liability of approximately $7.9 million
relating to these matters. Considerable uncertainty exists with
respect to these costs and, if adverse changes in circumstances
occur, potential liability may exceed the amount accrued as of
September 30, 2007. The time frame over which the accrued
amounts may be paid out, based on past history, is estimated to
be
15-20 years.
Regulatory matters: On October 11, 2007,
the Companys subsidiary, Arrow International, Inc.
(Arrow), received a corporate warning letter from
the U.S. Food and Drug Administration (FDA). The letter
cites three site-specific warning letters issued by the FDA in
2005 and subsequent inspections performed from June 2005 to
February 2007 at Arrows facilities in the United States.
The letter expresses concerns with Arrows quality systems,
including complaint handling, corrective and preventive action,
process and design validation, inspection and training
procedures. It also advises that Arrows corporate-wide
program to evaluate, correct and prevent quality system issues
has been deficient. Limitations on pre-market approvals and
certificates of foreign goods had previously been imposed on
Arrow based on prior inspections and the corporate warning
letter does not impose additional sanctions that are expected to
have a material financial impact on the Company.
Arrow has been actively working to address the FDAs
findings and has been conducting a thorough review of its
quality systems. Ongoing updates have been provided to the FDA
outlining corrective and preventive actions. In connection with
its acquisition of Arrow, completed on October 1, 2007, the
Company has developed an integration plan that includes the
commitment of significant resources to correct these
previously-identified regulatory issues and further improve
overall quality systems. The Company intends to promptly respond
to the warning letter.
While we believe we can remediate these issues in an expeditious
manner, there can be no assurances regarding the length of time
or cost it will take us to resolve these issues to the
satisfaction of the FDA. If our remedial actions are not
satisfactory to the FDA, we may have to devote additional
financial and human resources to our efforts, and the FDA may
take further regulatory actions against us, including, but not
limited to, seizing our product inventory, obtaining a court
injunction against further marketing of our products or
assessing civil monetary penalties.
Litigation: The Company is a party to various
lawsuits and claims arising in the normal course of business.
These lawsuits and claims include actions involving product
liability, intellectual property, employment and environmental
matters. Based on information currently available, advice of
counsel, established reserves and other resources, the Company
does not believe that any such actions are likely to be,
individually or in the aggregate, material to its business,
financial condition, results of operations or liquidity.
However, in the event of unexpected further developments, it is
possible that the ultimate resolution of these matters, or other
similar matters, if unfavorable, may be materially adverse to
the Companys business, financial condition, results of
operations or liquidity. Legal costs such as outside counsel
fees and expenses are charged to expense in the period incurred.
14
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Income taxes: Taxes on income from continuing
operations of $105.7 million during the third quarter of
2007 include discrete income tax charges incurred in
anticipation of the Arrow acquisition. Specifically, in
connection with funding the acquisition of Arrow, the Company
(i) repatriated approximately $197.0 million of cash
from foreign subsidiaries which had previously been deemed to be
permanently reinvested in the respective foreign jurisdictions;
and (ii) changed its position with respect to certain
additional previously untaxed foreign earnings to treat these
earnings as no longer permanently reinvested. These items
resulted in a discrete income tax charge in the third quarter of
2007 of approximately $90.2 million.
Uncertain tax positions: The total amount of
unrecognized tax benefits as of January 1, 2007, the date
of adoption of FIN No. 48, is approximately
$53.0 million. Of this amount, the total amount of
unrecognized tax benefits that, if recognized, would affect the
effective tax rate is approximately $28.7 million. The
Company recognizes potential accrued interest and penalties
related to unrecognized tax benefits from its global operations
in income tax expense. Accordingly, at January 1, 2007,
approximately $6.2 million of accrued interest and
penalties is included as a component of the total unrecognized
tax benefit recorded on the condensed consolidated balance
sheet. During the nine months ended September 30, 2007, the
Company recognized approximately $2.2 million in potential
interest associated with unrecognized tax benefits.
The taxable years that remain subject to examination by major
tax jurisdictions are as follows:
|
|
|
|
|
|
|
|
|
|
|
Beginning
|
|
|
Ending
|
|
|
United States
|
|
|
2000
|
|
|
|
2006
|
|
Canada
|
|
|
2002
|
|
|
|
2006
|
|
France
|
|
|
2000
|
|
|
|
2006
|
|
Germany
|
|
|
1998
|
|
|
|
2006
|
|
Italy
|
|
|
2000
|
|
|
|
2006
|
|
Malaysia
|
|
|
2000
|
|
|
|
2006
|
|
Sweden
|
|
|
2000
|
|
|
|
2006
|
|
United Kingdom
|
|
|
2004
|
|
|
|
2006
|
|
As a result of the outcome of ongoing or future examinations, or
due to the expiration of statutes of limitation for certain
jurisdictions, it is reasonably possible that the related
unrecognized tax benefits for tax positions taken could
materially change from those recorded as liabilities at
September 30, 2007. Based on the status of various
examinations by the relevant federal, state and foreign tax
authorities, the Company anticipates that certain examinations
may be concluded within twelve months of the reporting date of
the Companys condensed consolidated financial statements,
the most significant of which are in Germany. Management does
not anticipate the resolution of such examinations or the impact
of the expiration of statutes of limitation for certain
jurisdictions will have a material impact on previously recorded
unrecognized tax benefits.
Other: The Company has various purchase
commitments for materials, supplies and items of permanent
investment incident to the ordinary conduct of business. On
average, such commitments are not at prices in excess of current
market.
15
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
Note 12
|
Business
segment information
|
Information about continuing operations by business segment is
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 24,
|
|
|
September 30,
|
|
|
September 24,
|
|
|
|
2007
|
|
|
2006
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in thousands)
|
|
|
Segment data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
|
|
$
|
314,492
|
|
|
$
|
290,357
|
|
|
$
|
990,631
|
|
|
$
|
932,051
|
|
Medical
|
|
|
227,825
|
|
|
|
207,722
|
|
|
|
681,142
|
|
|
|
628,604
|
|
Aerospace
|
|
|
113,747
|
|
|
|
107,446
|
|
|
|
331,351
|
|
|
|
294,937
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
656,064
|
|
|
|
605,525
|
|
|
|
2,003,124
|
|
|
|
1,855,592
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
|
|
|
9,161
|
|
|
|
14,757
|
|
|
|
52,808
|
|
|
|
60,092
|
|
Medical
|
|
|
50,448
|
|
|
|
44,223
|
|
|
|
142,275
|
|
|
|
111,819
|
|
Aerospace
|
|
|
7,544
|
|
|
|
9,760
|
|
|
|
32,174
|
|
|
|
26,969
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment operating
profit(1)
|
|
|
67,153
|
|
|
|
68,740
|
|
|
|
227,257
|
|
|
|
198,880
|
|
Less: Corporate expenses
|
|
|
7,868
|
|
|
|
7,679
|
|
|
|
28,340
|
|
|
|
21,649
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating profit
|
|
|
59,285
|
|
|
|
61,061
|
|
|
|
198,917
|
|
|
|
177,231
|
|
Net (gain) loss on sales of assets
|
|
|
(207
|
)
|
|
|
(453
|
)
|
|
|
1,121
|
|
|
|
732
|
|
Restructuring and impairment charges
|
|
|
5,398
|
|
|
|
3,275
|
|
|
|
6,999
|
|
|
|
16,243
|
|
Minority interest
|
|
|
(7,680
|
)
|
|
|
(6,627
|
)
|
|
|
(22,416
|
)
|
|
|
(18,215
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before interest, taxes and
minority interest
|
|
$
|
61,774
|
|
|
$
|
64,866
|
|
|
$
|
213,213
|
|
|
$
|
178,471
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Segment operating profit includes a segments revenues
reduced by its materials, labor and other product costs along
with the segments selling, engineering and administrative
expenses and minority interest. Unallocated corporate expenses,
(gain) loss on sales of assets, restructuring and impairment
charges, interest income and expense and taxes on income are
excluded from the measure. |
|
|
Note 13
|
Discontinued
operations and assets held for sale
|
On June 29, 2007, the Company completed the sale of
Teleflex Aerospace Manufacturing Group (TAMG), a
precision-machined components business in its Aerospace Segment
for approximately $133.9 million, and recognized a gain of
approximately $48.6 million, net of taxes of approximately
$26.6 million. For financial statement purposes, the
results of operations and cash flows of this business have been
segregated from those of continuing operations and are presented
in the Companys condensed consolidated financial
statements as discontinued operations.
Revenues of discontinued operations were $0 million and
approximately $34.7 million for the three months ended
September 30, 2007 and September 24, 2006,
respectively, and approximately $68.4 million and
$101.9 million for the nine months ended September 30,
2007 and September 24, 2006, respectively. Operating income
from discontinued operations was $0 million and
approximately $2.4 million for the three months ended
September 30, 2007 and September 24, 2006,
respectively, and approximately $5.3 million and
$7.3 million for the nine months ended September 30,
2007 and September 24, 2006, respectively.
16
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
During the first nine months of 2007 and 2006 the Company
disposed of assets that met the criteria for held for sale
classification, and recognized gains of approximately
$0.8 million and $1.1 million in 2007 and 2006,
respectively.
Assets held for sale are comprised of the following:
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in thousands)
|
|
|
Assets held for sale:
|
|
|
|
|
|
|
|
|
Property, plant and equipment
|
|
$
|
2,760
|
|
|
$
|
10,185
|
|
|
|
|
|
|
|
|
|
|
Total assets held for sale
|
|
$
|
2,760
|
|
|
$
|
10,185
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 14
|
Subsequent
events
|
On October 1, 2007, the Company acquired all of the
outstanding capital stock of Arrow International, Inc.
(Arrow) for approximately $2.0 billion. Arrow
is a global provider of catheter-based access and therapeutic
products for critical and cardiac care. The transaction was
financed with cash, borrowings under a new senior secured
syndicated bank loan and proceeds received through the issuance
of privately placed notes. The syndicated bank loan agreement
includes a $1.4 billion term loan and a $400 million
revolving line of credit, both of which carry initial interest
rates of LIBOR + 150 basis points. The Company executed an
interest rate swap for $600 million of the term loan from a
floating rate to a fixed rate of 6.25%. The obligations under
the bank loan agreement have been guaranteed by certain of the
Companys domestic subsidiaries and have been secured
pursuant to a pledge of certain of the equity interests in the
Companys subsidiaries held by the Company and the
subsidiary guarantors. In addition, the Company amended its
existing private placement notes and issued $200 million in
new private placement notes. The new notes were issued in series
as follows: (i) $130,000,000 7.62% Series A Senior
Notes due October 1, 2012; (ii) $40,000,000 7.94%
Series B Senior Notes due October 1, 2014; and
(iii) $30,000,000 Floating Rate Series C Senior Notes
due October 1, 2012. The amended notes include the
following: (i) $150,000,000
Series 2004-1
Tranche A Senior Notes due 2011; (ii) $100, 000,000
Series 2004-1
Tranche B Senior Notes due 2014; (iii) $100,000,000
Series 2004-1
Tranche C Senior Notes due 2016; and (iv) $50,000,000
Senior Notes due October 25, 2012. The interest rates
payable on the amended notes were also modified in connection
with the foregoing transactions. Effective October 1, 2007,
(a) the 2004 Notes will bear interest on the outstanding
principal amount at the following rates: (i) 7.66% in
respect of the
Series 2004-1
Tranche A Senior Notes due 2011; (ii) 8.14% in respect
of the
Series 2004-1
Tranche B Senior Notes due 2014; and (iii) 8.46% in
respect of the
Series 2004-1
Tranche C Senior Notes due 2016; and (b) the 2002
Notes will bear interest on the outstanding principal amount at
the rate of 7.82% per annum. These initial rates will be reduced
by 0.25% after the Companys ratio of Consolidated Total
Indebtedness to Consolidated Actual EBITDA (as those terms are
defined in the amendments) is less than 3.50 to 1.00 for two
consecutive quarters, and by an additional 0.75% after such
ratio is less than 3.00 to 1.00 for two consecutive quarters.
The existing private placement notes and new notes rank pari
passu in right of repayment with the Companys obligations
under the bank loan agreement, are secured and guaranteed in the
same manner as the obligations under the bank loan agreement and
otherwise include terms that are substantially similar to those
set forth in the bank loan agreement.
On October 14, 2007, the Company and Kongsberg Automotive
Holding ASA (Kongsberg) entered into a Purchase
Agreement (the Purchase Agreement) pursuant to which
Kongsberg will acquire the Companys business units that
design and manufacture automotive and industrial driver
controls, motion systems and fluid handling systems (the
Business) for $560 million in cash (the
Sale). The purchase price is subject to possible
upward or downward adjustment based on certain provisions in the
Purchase Agreement relating to the working capital of the
Business, measured at the closing date of the Sale. Completion
of the Sale is subject to customary closing conditions. The Sale
is not subject to any financing condition, and is expected to
close by the end of 2007. The accompanying financial information
includes the operations of the business as a component of
continuing operations as the requirements for discontinued
operations treatment were not met at September 30, 2007.
Revenues for this business were $652 million and
$614 million for the first nine months of 2007 and 2006,
respectively.
17
|
|
Item 2.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
Forward-Looking
Statements
All statements made in this Quarterly Report on
Form 10-Q,
other than statements of historical fact, are forward-looking
statements. The words anticipate,
believe, estimate, expect,
intend, may, plan,
will, would, should,
guidance, potential,
continue, project, forecast,
confident, prospects, and similar
expressions typically are used to identify forward-looking
statements. Forward-looking statements are based on the
then-current expectations, beliefs, assumptions, estimates and
forecasts about our business and the industry and markets in
which we operate. These statements are not guarantees of future
performance and are subject to risks, uncertainties and
assumptions which are difficult to predict. Therefore, actual
outcomes and results may differ materially from what is
expressed or implied by these forward-looking statements due to
a number of factors, including changes in business relationships
with and purchases by or from major customers or suppliers,
including delays or cancellations in shipments; demand for and
market acceptance of new and existing products; our ability to
integrate acquired businesses into our operations, realize
planned synergies and operate such businesses profitably in
accordance with expectations; our ability to effectively execute
our restructuring programs; competitive market conditions and
resulting effects on revenues and pricing; increases in raw
material costs that cannot be recovered in product pricing; and
global economic factors, including currency exchange rates and
interest rates; difficulties entering new markets; and general
economic conditions. For a further discussion of the risks
relating to our business, see Item 1A of our Annual Report
on
Form 10-K
for the fiscal year ended December 31, 2006. We expressly
disclaim any obligation to update these forward-looking
statements, except as otherwise specifically stated by us or as
required by law or regulation.
Overview
We are focused on achieving consistent and sustainable growth
through the continued development of our core businesses and
carefully selected acquisitions. Our internal growth initiatives
include the development of new products, moving existing
products into adjacent markets and expanding market share. Our
core revenue grew approximately 3% in the third quarter of 2007
as compared to the same period in 2006, excluding the impacts of
currency, acquisitions and divestitures, reflecting core revenue
growth in all three segments.
Segment operating profit declined, however, approximately 2% in
the third quarter of 2007 compared to the same period in 2006.
This decline was due primarily to provisions for warranty and
other costs related to prior generation auxiliary power units
sold to the North American truck market, increased engineering
expense in advance of new product launches in businesses serving
the marine, automotive and industrial markets, continued
customer price reductions in automotive markets and increased
commodity costs, production inefficiencies related to lower
volume for cargo container and actuator products, which offset
the effects of improved cost and operational efficiencies,
higher volumes and improved sales mix in the Medical Segment.
On June 29, 2007, the Company completed the sale of
Teleflex Aerospace Manufacturing Group (TAMG), a
precision-machined components business in its Aerospace Segment
for $133.9 million, and recognized a gain of
$48.6 million, net of taxes of $26.6 million. For the
first nine months of 2007 and the comparable period of 2006, the
TAMG business has been presented in our condensed consolidated
financial statements as a discontinued operation.
On October 1, 2007, the Company acquired all of the
outstanding capital stock of Arrow International, Inc.
(Arrow) for approximately $2.0 billion
including fees and expenses. Arrow is a leading global provider
of catheter-based access and therapeutic products for critical
and cardiac care. The transaction has been financed with cash, a
senior secured syndicated bank loan and issuance of private
placement notes. The syndicated bank loan agreement includes a
$1.4 billion term loan and a $400 million revolving
line of credit, both of which carry initial interest rates of
LIBOR + 150 basis points. The company executed an interest
rate swap for $600 million of the term loan from floating
to a fixed rate of 6.25%. In addition, Teleflex amended its
existing private placement notes and issued $200 million in
new private placement notes with a blended interest rate of
under 8% and terms substantially similar to the syndicated bank
agreement. For additional information regarding the terms of our
financing arrangements, including terms relating to interest
rates, see Note 14 to our condensed consolidated financial
statements included in this Quarterly Report on
Form 10-Q.
As a result of this acquisition, the Companys interest
18
costs will increase significantly in the future due to an
approximate $2.0 billion increase in its net debt. The
Company will begin to report the results of Arrow in the fourth
quarter of 2007.
On October 14, 2007, the Company and Kongsberg Automotive
Holding ASA (Kongsberg) entered into a Purchase
Agreement (the Purchase Agreement) pursuant to which
Kongsberg will acquire the Companys business units that
design and manufacture automotive and industrial driver
controls, motion systems and fluid handling systems (the
Business) for $560 million in cash (the
Sale). The purchase price is subject to possible
upward or downward adjustment based on certain provisions in the
Purchase Agreement relating to the working capital of the
Business, measured at the closing date of the Sale. Completion
of the Sale is subject to customary closing conditions. The Sale
is not subject to any financing condition, and is expected to
close by the end of 2007.
Results
of Operations
Discussion of growth from acquisitions reflects the impact of a
purchased company up to twelve months beyond the date of
acquisition. Activity beyond the initial twelve months is
considered core growth. Core growth excludes the impact of
translating the results of international subsidiaries at
different currency exchange rates from year to year and the
comparable activity of divested companies within the most recent
twelve-month period. The following comparisons exclude the
impact of the TAMG business and a small medical business, which
have been presented in our condensed consolidated financial
results as discontinued operations.
Comparison
of the three and nine months ended September 30, 2007 and
September 24, 2006
Revenues increased approximately 8% in the third quarter of 2007
to $656.1 million from $605.5 million in the third
quarter of 2006. This increase was due to core growth, currency
movements and acquisitions of 3%, 3% and 2%, respectively.
Revenues increased approximately 8% in the first nine months of
2007 to $2.0 billion from $1.86 billion in the first
nine months of 2006. This increase was due to an increase of 3%
from core growth, 3% from currency movements and 2% from
acquisitions. The Commercial, Medical and Aerospace segments
comprised 48%, 35% and 17% of our revenues, respectively, for
the three months ended September 30, 2007 and comprised
49%, 34% and 17% of our revenues, respectively, for the first
nine months of 2007.
Gross profit as a percentage of revenues declined to 29.5% in
the third quarter of 2007 from 29.8% in the third quarter of
2006 largely due to approximately $4 million in provisions
for warranty and other costs related to prior generation
auxiliary power units sold to the North American truck market
and to approximately $0.8 million of one-time purchase
accounting adjustments in the Commercial Segment. Selling,
engineering and administrative expenses (operating expenses) as
a percentage of revenues were 19.7% for the first nine months of
2007 compared to 19.5% for the first nine months of 2006, and
were 19.3% of revenues in the third quarter of 2007 compared to
18.6% during the same period of a year ago. Higher operating
expenses were primarily attributable to engineering expense in
advance of new product launches in businesses serving the
marine, automotive and industrial markets, startup costs of a
Medical Segment European Shared Services center, quality
assurance investments made in the Medical Segment and the impact
of acquisitions and currency movements.
Interest expense declined slightly in the third quarter and
first nine months of 2007 principally as a result of lower debt
balances. Interest income increased in the third quarter and
first nine months of 2007 primarily due to higher amounts of
invested funds. The higher effective tax rate for the three and
nine months ending September 30, 2007, reflected discrete
income tax charges incurred in anticipation of the Arrow
acquisition. Specifically, in connection with funding the
acquisition of Arrow, the Company (i) repatriated
approximately $197.0 million of cash from foreign
subsidiaries which had previously been deemed to be permanently
reinvested in the respective foreign jurisdictions; and
(ii) changed its position with respect to certain
additional previously untaxed foreign earnings to treat these
earnings as no longer permanently reinvested. These items
resulted in a discrete income tax charge in the third quarter of
2007 of approximately $90.2 million. Also, the Company
remeasured certain deferred tax assets and liabilities as a
result of changes in enacted tax rates, resulting in the
recognition of a tax benefit of approximately $2.8 million
during the third quarter of 2007. Minority interest in
consolidated subsidiaries increased $1.1 million and
$4.2 million in the third quarter and first nine months of
2007, respectively, due to increased profits from consolidated
entities that are not wholly-owned. Loss from continuing
operations for the third quarter of 2007 was $56.8 million,
compared to income from continuing operations of
$34.7 million for the third quarter of 2006,
19
reflecting the discrete charges to income tax expense in the
third quarter of 2007. Income from continuing operations for the
first nine months of 2007 was $29.2 million, a decrease of
$67.0 million from the first nine months of 2006. Loss per
share from continuing operations was ($1.44) in the third
quarter of 2007 compared to diluted earnings per of $0.88 from
the third quarter of 2006. Diluted earnings per share from
continuing operations for the nine months ended
September 30, 2007 was $0.74 a decrease of $1.65 from the
comparable period last year.
We adopted the provisions of FASB Interpretation, or FIN,
No. 48 Accounting for Uncertainty in Income
Taxes an interpretation of FASB Statement
No. 109 on January 1, 2007. FIN No. 48
clarifies the accounting for uncertainty in income taxes
recognized in an enterprises financial statements in
accordance with Statement of Financial Accounting Standards, or
SFAS, No. 109, Accounting for Income Taxes.
FIN No. 48 requires that the impact of a tax position
be recognized in the financial statements if it is more likely
than not that the tax position will be sustained on tax audit,
based on the technical merits of the position.
FIN No. 48 also provides guidance on derecognition of
tax positions that do not meet the more likely than
not standard, classification of tax assets and
liabilities, interest and penalties, accounting in interim
periods, disclosure and transition. In connection with our
adoption of the provisions of FIN No. 48, we
recognized a charge of approximately $13.2 million to
retained earnings.
For additional information regarding our uncertain tax
positions, see Note 11 to our condensed consolidated
financial statements included in this Quarterly Report on
Form 10-Q.
In June 2006, we began certain restructuring initiatives that
affect all three of our operating segments. These initiatives
involve the consolidation of operations and a related reduction
in workforce at several of our facilities in Europe and North
America. We have determined to undertake these initiatives as a
means to improving operating performance and to better leverage
our existing resources. The charges, including changes in
estimates, associated with the 2006 restructuring program that
are included in restructuring and impairment charges during the
first nine months of both 2007 and 2006 approximated
$2.6 million, respectively. As of September 30, 2007,
we expect to incur future restructuring costs associated with
our 2006 restructuring program of between $3.0 million and
$4.0 million in our Commercial, Medical and Aerospace
segments through the second quarter of 2008.
During the first quarter of 2006, we began a restructuring
activity in our Aerospace Segment. The actions related to the
closure of a manufacturing facility, termination of employees
and relocation of operations. No charges associated with this
activity were included in restructuring and impairment charges
during the third quarter and first nine months of 2007. The
charges, including changes in estimates, associated with this
activity that are included in restructuring and impairment
charges during the third quarter first nine months of 2006
totaled $0.3 million and $0.6 million, respectively.
We do not expect to incur any additional restructuring costs
associated with this activity.
For additional information regarding our restructuring programs,
see Note 4 to our condensed consolidated financial
statements included in this Quarterly Report on
Form 10-Q.
Segment
Reviews
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 24,
|
|
|
% Increase/
|
|
|
September 30,
|
|
|
September 24,
|
|
|
% Increase/
|
|
|
|
2007
|
|
|
2006
|
|
|
(Decrease)
|
|
|
2007
|
|
|
2006
|
|
|
(Decrease)
|
|
|
Segment data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
|
|
$
|
314,492
|
|
|
$
|
290,357
|
|
|
|
8
|
|
|
$
|
990,631
|
|
|
$
|
932,051
|
|
|
|
6
|
|
Medical
|
|
|
227,825
|
|
|
|
207,722
|
|
|
|
10
|
|
|
|
681,142
|
|
|
|
628,604
|
|
|
|
8
|
|
Aerospace
|
|
|
113,747
|
|
|
|
107,446
|
|
|
|
6
|
|
|
|
331,351
|
|
|
|
294,937
|
|
|
|
12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
656,064
|
|
|
$
|
605,525
|
|
|
|
8
|
|
|
$
|
2,003,124
|
|
|
$
|
1,855,592
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
|
|
$
|
9,161
|
|
|
$
|
14,757
|
|
|
|
(38
|
)
|
|
$
|
52,808
|
|
|
$
|
60,092
|
|
|
|
(12
|
)
|
Medical
|
|
|
50,448
|
|
|
|
44,223
|
|
|
|
14
|
|
|
|
142,275
|
|
|
|
111,819
|
|
|
|
27
|
|
Aerospace
|
|
|
7,544
|
|
|
|
9,760
|
|
|
|
(23
|
)
|
|
|
32,174
|
|
|
|
26,969
|
|
|
|
19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
|
$
|
67,153
|
|
|
$
|
68,740
|
|
|
|
(2
|
)
|
|
$
|
227,257
|
|
|
$
|
198,880
|
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20
The percentage increases or (decreases) in revenues during the
three and nine months ended September 30, 2007 compared to
the respective periods ending September 24, 2006 were due
to the following factors:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% Increase/ (Decrease)
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
Commercial
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Total
|
|
|
Commercial
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Total
|
|
|
Core growth
|
|
|
2
|
|
|
|
3
|
|
|
|
4
|
|
|
|
3
|
|
|
|
1
|
|
|
|
3
|
|
|
|
10
|
|
|
|
3
|
|
Currency impact
|
|
|
3
|
|
|
|
3
|
|
|
|
2
|
|
|
|
3
|
|
|
|
3
|
|
|
|
3
|
|
|
|
2
|
|
|
|
3
|
|
Acquisitions
|
|
|
3
|
|
|
|
4
|
|
|
|
|
|
|
|
2
|
|
|
|
2
|
|
|
|
2
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Change
|
|
|
8
|
|
|
|
10
|
|
|
|
6
|
|
|
|
8
|
|
|
|
6
|
|
|
|
8
|
|
|
|
12
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following is a discussion of our segment operating results.
Comparison
of the three and nine months ended September 30, 2007 and
September 24, 2006
Commercial
Commercial Segment revenues grew approximately 8% in the third
quarter to $314.5 million, from $290.4 million in the
same period last year. Foreign currency fluctuations contributed
approximately 3% of this growth, acquisitions contributed
another 3%, and core growth increased 2%. Commercial Segment
core revenue growth was driven by increased sales of driver
controls and related products for the recreational marine
aftermarket in North America and Europe, fluid systems for the
automotive and truck markets and strength in sales of driver
controls for truck and bus markets in Europe and Asia. These
more than offset slower core growth in rigging services, where
U.S. Gulf Coast rebuilding activities in last years
third quarter caused unfavorable revenue comparisons.
For the nine month period, Commercial segment revenues grew
approximately 6% from $932.1 million to
$990.6 million. Currency changes contributed 3% and
acquisitions contributed 2%. The Commercial Segment generated
modest 1% core growth during the nine month period as higher
volumes in the marine aftermarket and increased demand for
industrial products in the international truck and bus markets
were offset by expected volume declines in automotive markets,
the planned phase-out of certain platforms, and the
previously-mentioned unfavorable comparisons in the quarter for
rigging services.
During the third quarter, operating profit in the Commercial
segment declined 38%, from $14.8 million to
$9.2 million, principally due to approximately
$4 million in provisions for warranty and other costs
related to prior generation auxiliary power units sold to the
North American truck market and to approximately
$0.8 million of
one-time
purchase accounting adjustments. In addition, operating profit
was negatively impacted by increased engineering expense in
advance of new product launches in businesses serving the
marine, automotive and industrial markets as well as to
continued customer price reductions in automotive markets and
increased commodity costs.
For the nine month period, Commercial segment operating profit
declined 12%, from $60.1 million to $52.8 million, as
a result of lower volumes and customer price reductions in
automotive markets, increased commodity costs in the automotive
and marine markets, and the previously-mentioned provision for
warranty costs for auxiliary power units.
Medical
Medical segment revenues grew 10% in the third quarter to
$227.8 million, from $207.7 million in the same period
last year. Foreign currency fluctuations contributed
approximately 3% of this growth, acquisitions contributed
another 4%, and core growth was 3%. The increase in core
revenues during the quarter was primarily due to strong sales of
disposable products for airway management and urology
applications in European markets, increased sales of respiratory
care products in North America, and increased sales of specialty
devices and sutures to medical device manufacturers while sales
of orthopedic instruments to medical device manufacturers
declined when compared to the prior year quarter.
21
For the first nine months of 2007, Medical Segment revenues grew
approximately 8% to $681.1 million, from
$628.6 million in the same period last year. Acquisitions
contributed 2% of this growth, while foreign currency
fluctuations contributed an additional 3%. Core revenue growth
of 3% resulted from strong sales of disposable products for
airway management, respiratory and urology in international
hospital markets as well as expansion of disposable and surgical
product distribution in Asian hospital markets.
Operating profit in the Medical Segment increased 14%, from
$44.2 million to $50.4 million, during the third
quarter as a result of improved cost and operational
efficiencies, higher volumes and the impact of the phasing out
of lower margin surgical product lines and product lines sold to
medical device manufacturers.
For the nine month period, Medical Segment operating profit
increased 27.2%, from $111.8 million to
$142.3 million, as a result of operating efficiencies
implemented in the second half of 2006 as well as increased
sales volume which drove increased operating leverage.
Aerospace
Aerospace Segment revenues grew 6% in the third quarter of 2007
to $113.7 million, from $107.4 million in the same
period last year. Foreign currency fluctuations contributed
approximately 2% of this growth and core growth was 4%. The
increase in core revenues reflects increased demand for repair
services and growth in demand for wide body cargo systems and
cargo aftermarket spares product offerings which more than
offset lower volumes for cargo containers and actuators.
For the first nine months of 2007, Aerospace Segment revenues
grew 12% to $331.4 million, from $294.9 million in the
same period last year. Foreign currency fluctuations contributed
approximately 2% of this growth and core growth was 10%. Core
growth was primarily attributable to strong end markets,
particularly for wide body cargo systems and narrow body cargo
loading systems, combined with steady increases in sales volume
for aftermarket spares and repairs throughout the year.
Segment operating profit decreased 23% in the third quarter of
2007, from $9.8 million to $7.5 million, principally
due to approximately $2 million of production
inefficiencies related to lower volume for cargo container and
actuator products and the impact of the sales mix being weighted
more toward lower margin wide body cargo system sales and
replacement parts in the repairs business.
For the first nine months of 2007, operating profits increased
19% from $27 million to $32.2 million, driven by
higher volume, productivity improvements, cost control efforts
in cargo systems and repairs, and the positive impact of
restructuring in repair services.
Liquidity
and Capital Resources
Operating activities from continuing operations provided net
cash of $208.0 million during the first nine months of
2007. Changes in our operating assets and liabilities of
$79.6 million during the first nine months of 2007 reflect
the discrete income tax charges incurred in anticipation of the
Arrow acquisition. Specifically, in connection with funding the
acquisition of Arrow, the Company (i) repatriated
approximately $197.0 million of cash from foreign
subsidiaries which had previously been deemed to be permanently
reinvested in the respective foreign jurisdictions; and
(ii) changed its position with respect to certain
additional previously untaxed foreign earnings to treat these
earnings as no longer permanently reinvested. These items
resulted in a discrete income tax charge in the third quarter of
2007 of approximately $90.2 million, which affected income
taxes payable and deferred income taxes. Our financing
activities from continuing operations during the first nine
months of 2007 consisted primarily of proceeds from long-term
borrowings of $49.2 million, decreases in long-term
borrowings and notes payable and current borrowings of
approximately $38.0 million, proceeds from stock
compensation plans of $23.2 million, payment of dividends
of $36.3 million and payments to minority interest
shareholders of $21.3 million. Our investing activities
from continuing operations during the first nine months of 2007
consisted primarily of capital expenditures of
$37.1 million, payments for businesses acquired and
investments in affiliates of $43.7 million, proceeds from
the sale of businesses and assets of $142.3 million. Net
cash provided by discontinued operations was $1.0 million
in the first nine months of 2007.
22
We use an accounts receivable securitization program to gain
access to enhanced credit markets and reduce financing costs. As
currently structured, we sell certain trade receivables on a
non-recourse basis to a consolidated special purpose entity,
which in turn sells an interest in those receivables to a
commercial paper conduit. The conduit issues notes secured by
that interest to third party investors. The assets of the
special purpose entity are not available to satisfy our
obligations. In accordance with the provisions of Statement of
Financial Accounting Standards, or SFAS, No. 140,
Accounting for Transfers and Servicing of Financial Assets
and Extinguishments of Liabilities, transfers of assets
under the program qualify as sales of receivables and
accordingly, $39.7 million and $40.1 million of
accounts receivable and the related amounts previously recorded
in notes payable were removed from the condensed consolidated
balance sheet at September 30, 2007 and December 31,
2006, respectively.
On June 14, 2007, the Companys Board of Directors
authorized the repurchase of up to $300 million of
outstanding Company common stock. Repurchases of Company stock
under the program may be made from time to time in the open
market and may include privately-negotiated transactions as
market conditions warrant and subject to regulatory
considerations. The stock repurchase program has no expiration
date and the Companys ability to execute on the program
will depend on, among other factors, cash requirements for
acquisitions, cash generation from operations, debt repayment
obligations, market conditions and regulatory requirements. In
addition under the senior loan agreements entered into
October 1, 2007, the Company is subject to certain
restrictions relating to its ability to repurchase shares in the
event the Companys consolidated leverage ratio exceeds
certain levels, which may further limit the Companys
ability to repurchase shares under this program. Through
September 30, 2007, no shares have been purchased under
this plan.
The following table provides our net debt to total capital ratio:
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
|
(Dollars in thousands)
|
|
|
Net debt includes:
|
|
|
|
|
|
|
|
|
Current borrowings
|
|
$
|
80,562
|
|
|
$
|
31,022
|
|
Long-term borrowings
|
|
|
455,878
|
|
|
|
487,370
|
|
|
|
|
|
|
|
|
|
|
Total debt
|
|
|
536,440
|
|
|
|
518,392
|
|
Less: Cash and cash equivalents
|
|
|
497,724
|
|
|
|
248,409
|
|
|
|
|
|
|
|
|
|
|
Net debt
|
|
$
|
38,716
|
|
|
$
|
269,983
|
|
|
|
|
|
|
|
|
|
|
Total capital includes:
|
|
|
|
|
|
|
|
|
Net debt
|
|
$
|
38,716
|
|
|
$
|
269,983
|
|
Shareholders equity
|
|
|
1,290,060
|
|
|
|
1,189,421
|
|
|
|
|
|
|
|
|
|
|
Total capital
|
|
$
|
1,328,776
|
|
|
$
|
1,459,404
|
|
|
|
|
|
|
|
|
|
|
Percent of net debt to total capital
|
|
|
2.9
|
%
|
|
|
18.5
|
%
|
The decline in our percent of net debt to total capital for
September 30, 2007 as compared to December 31, 2006 is
primarily due to the proceeds received from the sale of TAMG in
June 2007 and cash generated from operations.
In connection with the October 1, 2007 acquisition of all
of the outstanding capital stock of Arrow International for
approximately $2.0 billion, the Companys net debt
increased approximately $2.0 billion. The Companys
debt agreements contain covenants that limit the Companys
ability to enter into certain transactions such as increasing
additional indebtedness, making share repurchases, establishing
liens and entering into acquisitions and dispositions. The
Company is required to report compliance with certain financial
covenants to its lenders on a quarterly basis. Under these
covenants, the Company is required to maintain a leverage ratio
(total indebtedness to earnings before interest, taxes,
depreciation and amortization EBITDA and an interest
coverage ratio (EBITDA to interest expense as defined in the
credit agreement). Certain covenants under the debt agreements
become less restrictive when the Companys leverage is
reduced below a certain level. For a description of the debt
23
incurred in connection with the acquisition of Arrow see
Note 14 to our condensed consolidated financial statements
included in this Quarterly Report on
Form 10-Q.
As of October 1, 2007, the aggregate amount of debt
maturing for each year is as follows (dollars in millions):
|
|
|
|
|
2007
|
|
$
|
57
|
|
2008
|
|
|
164
|
|
2009
|
|
|
141
|
|
2010
|
|
|
140
|
|
2011
|
|
|
290
|
|
2012
|
|
|
1,212
|
|
2013 and thereafter
|
|
|
240
|
|
We believe that our cash flow from operations and our ability to
access additional funds through existing and new credit
facilities will enable us to fund our operating requirements and
capital expenditures and meet the obligations of our credit
agreements.
|
|
Item 3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
There have been no significant changes in market risk for the
quarter ended September 30, 2007. See the information set
forth in Part II, Item 7A of the Companys Annual
Report on
Form 10-K
for the fiscal year ended December 31, 2006.
|
|
Item 4.
|
Controls
and Procedures
|
(a) Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive
Officer and Chief Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures as of the end of the
period covered by this report. Based on that evaluation, the
Chief Executive Officer and Chief Financial Officer concluded
that our disclosure controls and procedures as of the end of the
period covered by this report are functioning effectively to
provide reasonable assurance that the information required to be
disclosed by us in reports filed under the Securities Exchange
Act of 1934 is (i) recorded, processed, summarized and
reported within the time periods specified in the SECs
rules and forms and (ii) accumulated and communicated to
our management, including the Chief Executive Officer and Chief
Financial Officer, as appropriate to allow timely decisions
regarding disclosure. A controls system cannot provide absolute
assurance that the objectives of the controls system are met,
and no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, within a
company have been detected.
(b) Change in Internal Control over Financial Reporting
No change in our internal control over financial reporting
occurred during our most recent fiscal quarter that has
materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.
24
PART II
OTHER INFORMATION
|
|
Item 1.
|
Legal
Proceedings
|
On October 11, 2007, the Companys subsidiary, Arrow
International, Inc. (Arrow), received a corporate
warning letter from the U.S. Food and Drug Administration
(FDA). The letter cites three site-specific warning letters
issued by the FDA in 2005 and subsequent inspections performed
from June 2005 to February 2007 at Arrows facilities in
the United States. The letter expresses concerns with
Arrows quality systems, including complaint handling,
corrective and preventive action, process and design validation,
inspection and training procedures. It also advises that
Arrows corporate-wide program to evaluate, correct and
prevent quality system issues has been deficient. Limitations on
pre-market approvals and certificates of foreign goods had
previously been imposed on Arrow based on prior inspections and
the corporate warning letter does not impose additional
sanctions that are expected to have a material financial impact
on the Company.
Arrow has been actively working to address the FDAs
findings and has been conducting a thorough review of its
quality systems. Ongoing updates have been provided to the FDA
outlining corrective and preventive actions. In connection with
its acquisition of Arrow, completed on October 1, 2007, the
Company has developed an integration plan that includes the
commitment of significant resources to correct these
previously-identified regulatory issues and further improve
overall quality systems. The Company intends to promptly respond
to the warning letter.
While we believe we can remediate these issues in an expeditious
manner, there can be no assurances regarding the length of time
or cost it will take us to resolve these issues to the
satisfaction of the FDA. If our remedial actions are not
satisfactory to the FDA, we may have to devote additional
financial and human resources to our efforts, and the FDA may
take further regulatory actions against us, including, but not
limited to, seizing our product inventory, obtaining a court
injunction against further marketing of our products or
assessing civil monetary penalties.
In addition, we are a party to various lawsuits and claims
arising in the normal course of business. These lawsuits and
claims include actions involving product liability, intellectual
property, employment and environmental matters. Based on
information currently available, advice of counsel, established
reserves and other resources, we do not believe that any such
actions are likely to be, individually or in the aggregate,
material to our business, financial condition, results of
operations or liquidity. However, in the event of unexpected
further developments, it is possible that the ultimate
resolution of these matters, or other similar matters, if
unfavorable, may be materially adverse to our business,
financial condition, results of operations or liquidity.
There have been no significant changes in risk factors for the
quarter ended September 30, 2007. See the information set
forth in Part I, Item 1A of the Companys Annual
Report on
Form 10-K
for the fiscal year ended December 31, 2006.
|
|
Item 2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
Not applicable.
|
|
Item 3.
|
Defaults
Upon Senior Securities
|
Not applicable.
|
|
Item 4.
|
Submission
of Matters to a Vote of Security Holders
|
Not applicable.
|
|
Item 5.
|
Other
Information
|
Not applicable.
25
The following exhibits are filed as part of this report:
|
|
|
|
|
|
|
Exhibit No.
|
|
|
|
Description
|
|
|
10
|
.1
|
|
|
|
Purchase Agreement, dated October 14, 2007, between
Teleflex Incorporated and Kongsberg Automotive Holding ASA.
|
|
10
|
.2
|
|
|
|
Letter to John Sickler, dated August 28, 2006, RE: Bonus
Compensation.
|
|
31
|
.1
|
|
|
|
Certification of Chief Executive Officer pursuant to
Rule 13a 14(a) under the Securities Exchange
Act of 1934.
|
|
31
|
.2
|
|
|
|
Certification of Chief Financial Officer pursuant to
Rule 13a 14(a) under the Securities Exchange
Act of 1934.
|
|
32
|
.1
|
|
|
|
Certification of Chief Executive Officer pursuant to
Rule 13a 14(b) under the Securities Exchange
Act of 1934.
|
|
32
|
.2
|
|
|
|
Certification of Chief Financial Officer, Pursuant to
Rule 13a 14(b) under the Securities Exchange
Act of 1934.
|
26
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
TELEFLEX INCORPORATED
Jeffrey P. Black
Chairman and
Chief Executive Officer
(Principal Executive Officer)
Kevin K. Gordon
Executive Vice President and
Chief Financial Officer
(Principal Financial Officer)
|
|
|
|
By:
|
/s/ Charles
E. Williams
|
Charles E. Williams
Corporate Controller and
Chief Accounting Officer
(Principal Accounting Officer)
Dated: November 1, 2007
27